Human Placental LRP5 and Sclerostin are Increased in Gestational Diabetes Mellitus Pregnancies
The Journal of Clinical Endocrinology & Metabolism · 18.09.2023 · 108 (10) · 2666-2675
DOI: 10.1210/clinem/dgad164 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 22.03.2023. Verfasst von Anna Papadopoulou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Third Department of Pediatrics, National and Kapodistrian University of Athens, Medical School, University General Hospital "Attikon," GR-12464, Athe…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes, Gestational. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National and Kapodistrian University.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
The low-density lipoprotein receptor-related protein 5 (LRP5) and its inhibitor sclerostin, are key components of bone metabolism and potential contributors to type 2 diabetes mellitus susceptibility. This study aims at evaluating the expression of placental LRP5 and sclerostin in pregnancies with gestational diabetes mellitus (GDM) and investigate possible associations with umbilical sclerostin concentrations and clinical outcomes in mothers and their neonates.
Methods
Twenty-six GDM-mothers and 34 non-GDM mothers of Caucasian origin and their neonates admitted in a gynecology and obstetrics department of a university hospital were included in this study. Demographic data and maternal fasting glucose concentrations (24-28 weeks of gestation) were retrieved from the patients’ medical records. Placental LRP5 was determined by immunohistochemistry (IHC) and Western blotting analysis; placental sclerostin was determined by IHC. Umbilical serum sclerostin concentrations were measured by ELISA.
Results
Placental sclerostin IHC intensity values were positively correlated with LRP5 values as detected either by IHC (r = 0.529; P < .001) or Western blotting (r = 0.398; P = .008), with pregestational maternal body mass index values (r = 0.299; P = .043) and with maternal fasting glucose concentrations (r = 0.475; P = .009). Placental sclerostin and LRP5 were significantly greater in GDM compared with non-GDM placentas (histo-score: 65.08 ± 17.09 vs 11.45 ± 2.33, P < .001; 145.53 ± 43.74 vs 202.88 ± 58.65, P < .001; respectively).
Discussion
Sclerostin and LRP5 were detected in human placentas. The overexpression of placental sclerostin and LRP5 values in GDM compared with non-GDM pregnancies, as well as the positive association of placental sclerostin values with pregestational maternal body mass index and maternal fasting glucose concentrations may indicate the development of an adaptive mechanism in face of maternal hyperglycemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Third Department of Pediatrics, National and Kapodistrian University of Athens, Medical School, University General Hospital "Attikon," GR-12464, Athens, Greece.
- Department of Clinical Biochemistry, National and Kapodistrian University of Athens, Medical School, University General Hospital "Attikon," GR-12464, Athens, Greece.
- Department of Pathology, National and Kapodistrian University of Athens, Medical School, GR-11527 Athens, Greece.
- Third Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Medical School, University General Hospital "Attikon," Athens, Greece.
- Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, 17676 Athens, Greece.
- Diabetes Mellitus and Metabolism Unit, ARETAION Hospital, Medical School, National and Kapodistrian University of Athens, GR-11528, Athens, Greece.
ORCID-Profile: Anna Papadopoulou
Förderung
- National and Kapodistrian University
Zitieren
APA
Papadopoulou, A., Thymara, E., Maratou, E., Kanellopoulos, G., Papaevangelou, V., Kalantaridou, S., Kanellakis, S., Triantafyllidou, P., Valsamakis, G., & Mastorakos, G. (2023). Human Placental LRP5 and Sclerostin are Increased in Gestational Diabetes Mellitus Pregnancies. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2666-2675. https://doi.org/10.1210/clinem/dgad164
Vancouver
Papadopoulou A, Thymara E, Maratou E, Kanellopoulos G, Papaevangelou V, Kalantaridou S, et al. Human Placental LRP5 and Sclerostin are Increased in Gestational Diabetes Mellitus Pregnancies. The Journal of Clinical Endocrinology & Metabolism. 2023;108(10):2666-2675. doi:10.1210/clinem/dgad164
BibTeX
@article{Papadopoulou2023,
author = {Papadopoulou, Anna and Thymara, Eirini and Maratou, Eirini and Kanellopoulos, George and Papaevangelou, Vasiliki and Kalantaridou, Sophia and Kanellakis, Spyridon and Triantafyllidou, Pinelopi and Valsamakis, George and Mastorakos, George},
title = {Human Placental LRP5 and Sclerostin are Increased in Gestational Diabetes Mellitus Pregnancies},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {10},
pages = {2666--2675},
doi = {10.1210/clinem/dgad164}
}
EUVIMED